Blood Type & Screen, Prenatal Workup




Test Mnemonic

TSPN

CPT Codes

  • 86850 - QTY (1)
  • 86900 - QTY (1)
  • 86901 - QTY (1)

LOINC ®

34532-2

Aliases

  • Prenatal Ab Profile (blood type & screen)

Includes

  • ABO/Rh(D)
  • Antibody Screen
  • Rh Titer (if indicated)

Performing Laboratory

Cleveland Clinic Laboratories


Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
6 mLWhole bloodEDTA (Pink) AmbientDo not use serum separator tubes.

Alternate Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
5 mLWhole bloodEDTA (Lavender) AmbientDo not use serum separator tubes.

Stability

Environmental Condition Description
Ambient3 days
Refrigerated3 days
FrozenUnacceptable

Days Performed

Sun - Sat

Turnaround Time

4 hours

Methodology

Name Description
Agglutination 

Reference Range

Special Info

Those specimens with a positive antibody screen will have antibody identification performed and will incur additional fees. Antibody may be too weak to be detected and/or identified. Antibody Titer will be done if indicated. All blood bank samples must be labeled with the patient’s full name, date of birth, medical record number (or other unique number), date and time of sample collection, and the employee ID of the phlebotomist. Please see internal operating procedures for specimens collected outside of the Cleveland Clinic health system.

Clinical Info

Identification of risk of hemolytic disease of the newborn. If the antibody screen is positive and the antibody has been associated with hemolytic disease of the fetus and newborn, it will reflex to do the antibody titration. The direct antiglobulin test detects in vivo sensitization of red cells with IgG or complement. Indications include transfusion reaction, hemolytic disease of the fetus and newborn, passenger lymphocyte syndrome following stem cell or solid organ transplantation, and immune hemolytic anemia. If IgG sensitization is detected, depending on the clinical situation, eluate testing for new red cell alloantibodies may be required.